Medtronic (NYSE:MDT) said today that Health Canada granted a license for the enhanced Enlite glucose sensor, part of the medical device company’s MiniMed Veo integrated insulin pump and continuous glucose monitoring system.

That means the enhanced Enlite sensor will be available to patients north of the border in early October, according to a press release.

The enhanced version’s implanted volume is 80% smaller than prior versions, according to the release, and the company improved the Enlite’s sensor-to-transmitter connection and retooled the adhesive patch to help reduce skin irritation.

"Enhanced Enlite is the next step in delivering CGM technology that provides patients with a more advanced sensor performance and improved comfort. At Medtronic, we’re committed to developing technology that improves clinical outcomes for people living with diabetes. This technology innovation, combined with the clinically proven Low Glucose Suspend in the Medtronic MiniMed Veo insulin pump system, marks another critical milestone on the road towards the artificial pancreas," Medtronic Diabetes CMO Dr. Francine Kaufman said in prepared remarks.

Medtronic said the Veo system includes a "low glucose suspend" feature designed to reduce the risk of a hypoglycemic incident, a potentially fatal condition in which a patient’s blood glucose level becomes too low. The enhanced Enlite sensor has not been approved for sale in the U.S., the company said.